HighTower Advisors LLC Takes $484,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)

HighTower Advisors LLC acquired a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,514 shares of the biotechnology company’s stock, valued at approximately $484,000.

Several other large investors have also recently added to or reduced their stakes in ASND. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $30,000. Jones Financial Companies Lllp raised its holdings in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Blue Trust Inc. raised its holdings in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 328 shares in the last quarter. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S in the third quarter worth approximately $60,000. Finally, GAMMA Investing LLC boosted its stake in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ASND shares. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective on the stock. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a report on Tuesday, February 18th. Evercore ISI raised their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, March 18th. Finally, The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $204.64.

Ascendis Pharma A/S Trading Down 2.1 %

Shares of Ascendis Pharma A/S stock opened at $154.68 on Monday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The company has a market cap of $9.39 billion, a P/E ratio of -21.79 and a beta of 0.62. The stock has a 50-day moving average price of $144.16 and a 200 day moving average price of $137.34.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. On average, equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.